NEOM’s volume over the past week has been phenomenal and trading at a record pace giving all types of investors opportunities to make some big gains. But it will be the long term players that will see the big rewards and they are in good company.
There has been a lot of buzzing with Patrick Soon-Shiong’s recent filing showing a $3 million purchase of NEOM in the open market, and currently sitting on over 25% ownership. It will be no surprise to see this percentage increase substantially and we will all know what Mr. Soon-Shiong’s intentions are shortly.
About Patrick Soon-Shiong
Patrick Soon-Shiong is a rarity. He is the only physician on the Forbes 400 list to have made billions in biotech. He developed a new delivery method to administer Paclitaxel, a widely-used breast cancer drug. His net worth is estimated at $7 billion, which he made by selling two drug companies within the past three years. Altogether, he is one of only three biotech billionaire entrepreneurs in the U.S.
Patrick Soon-Shiong, M.D., is a South African-born Chinese American physician, surgeon, scientist and inventor who has pioneered revolutionary new treatments for diabetes and cancer. He is a named inventor on more than 50 patents and the author of more than 100 scientific papers. He developed the first encapsulated islet cell transplantation treatment for diabetes and the first nanoparticle albumin-bound FDA-approved oncology drug. He is the founder and former chief executive officer of two NASDAQ-listed, multi-billion dollar pharmaceutical companies.
Is it possible Mr. Soon-Shiong is making a takeover attempt?
Last traded at $0.0337 and close to 100% gains since Mr. Soon-Shiong holding disclosure, we are definitely looking at much higher prices with these big guns backing NEOM. Continue reading